Department of Surgery, Division of Oncology and Abdominal Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Br J Surg. 2011 Mar;98(3):436-41. doi: 10.1002/bjs.7361. Epub 2010 Dec 15.
Radioimmunotherapy (RIT) has been shown to reduce the incidence of local recurrence of colorectal cancer in an experimental model. The aim of the present study was to investigate the survival benefit of RIT compared with chemotherapy.
An anastomosis was constructed in male Wag/Rij rats after intraluminal injection of CC531 tumour cells. The therapeutic efficacy of (177) Lu-labelled MG1 (single intravenous dose of 300 MBq/kg, n = 20) was compared with that of 5-fluorouracil-based chemotherapy (6 weekly cycles administered intraperitoneally, n = 20) and no treatment (n = 20). The primary endpoint was survival. Toxicity was monitored by bodyweight measurement.
Both chemotherapy and RIT affected bodyweight, but the weight of animals in the RIT group remained significantly higher than in the chemotherapy group (median slope of bodyweight plot 0·48 versus 0·30 g/day; P < 0·001). Kaplan-Meier analysis showed that overall survival in the RIT and chemotherapy groups was significantly better than that in the control group (50 and 46 per cent versus 25 per cent respectively after 170 days; P = 0·024 and P = 0·029). Survival after treatment with RIT did not differ from that after chemotherapy (P = 0·911).
RIT is as effective as chemotherapy in experimental colorectal cancer.
放射免疫疗法（RIT）已被证明可降低结直肠癌实验模型中的局部复发率。本研究旨在探讨 RIT 与化疗相比的生存获益。
雄性 Wag/Rij 大鼠经腔内注射 CC531 肿瘤细胞后构建吻合口。比较（177）Lu 标记的 MG1（单次静脉剂量 300MBq/kg，n=20）与基于 5-氟尿嘧啶的化疗（每周腹腔内给予 6 个周期，n=20）和无治疗（n=20）的治疗效果。主要终点是生存。通过体重测量监测毒性。
化疗和 RIT 均影响体重，但 RIT 组动物的体重明显高于化疗组（体重图中位数斜率分别为 0.48 与 0.30g/天；P<0.001）。Kaplan-Meier 分析显示，RIT 和化疗组的总生存率明显高于对照组（170 天后分别为 50%和 46%与 25%；P=0.024 和 P=0.029）。RIT 治疗后的生存率与化疗后无差异（P=0.911）。
RIT 与化疗在实验性结直肠癌中同样有效。
